Disodium edetate 150 mg/mL (Added as disodium edetate hydrous 166mg) - søkeresultat

USA - engelsk - NLM (National Library of Medicine)

etidronate disodium- etidronate disodium tablet

carilion materials management - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

USA - engelsk - NLM (National Library of Medicine)

osphos- clodronate disodium injection, solution

dechra veterinary products - clodronate disodium (unii: n030400h8j) (clodronic acid - unii:0813bz6866) - clodronate disodium 60 mg in 1 ml - indication: for the control of clinical signs associated with navicular syndrome in horses. contraindications: horses with hypersensitivity to clodronate disodium should not receive osphos. do not use in horses with impaired renal function or with a history of renal disease.

USA - engelsk - NLM (National Library of Medicine)

pamidronate disodium injection pamidronate disodium- pamidronate disodium injection injection

akorn-strides, llc - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - injection - 3 mg in 1 ml - pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. diuretic therapy should not be employed prior to correction of hypovolemia. the safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions h

USA - engelsk - NLM (National Library of Medicine)

pamidronate disodium injection, solution

generamedix, inc. - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - injection, solution - 3 mg in 1 ml - pamidronate disodium in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. diuretic therapy should not be employed prior to correction of hypovolemia. the safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions ha

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alimta pemetrexed (as disodium) 100 mg powder for injection vial

eli lilly australia pty ltd - pemetrexed disodium heptahydrate, quantity: 151.7 mg - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; water for injections; sodium hydroxide - malignant pleural mesothelioma. alimta, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer. alimta in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.